BioWorld

Nov. 6, 2007

Deaths End Novacea's Prostate Cancer Trial

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today) Read More

Lead Therapeutics' Series A: $17M For Research In China

Immune Proteins 'Moonlight' In Brain Development, Repair

Favrille Adding $21M Via Direct Offering For FavId

Liver Disease Roundup

Other News To Note

American Heart Assoc. Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...